RYBELSUS is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Semaglutide.
Product ID | 0169-4303_27f15fac-7d98-4114-a2ec-92494a91da98 |
NDC | 0169-4303 |
Product Type | Human Prescription Drug |
Proprietary Name | RYBELSUS |
Generic Name | Oral Semaglutide |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2019-09-20 |
Marketing Category | NDA / NDA |
Application Number | NDA213051 |
Labeler Name | Novo Nordisk |
Substance Name | SEMAGLUTIDE |
Active Ingredient Strength | 3 mg/1 |
Pharm Classes | GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2019-09-20 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA213051 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-09-20 |
Marketing Category | NDA |
Application Number | NDA213051 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-09-20 |
Marketing Category | NDA |
Application Number | NDA213051 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-09-20 |
Marketing Category | NDA |
Application Number | NDA213051 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-09-20 |
Ingredient | Strength |
---|---|
SEMAGLUTIDE | 3 mg/1 |
SPL SET ID: | 27f15fac-7d98-4114-a2ec-92494a91da98 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0169-4303 | RYBELSUS | Oral Semaglutide |
0169-4307 | RYBELSUS | Oral Semaglutide |
0169-4314 | RYBELSUS | Oral Semaglutide |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RYBELSUS 79242284 5682853 Live/Registered |
Novo Nordisk A/S 2018-07-09 |